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ABSTRACT
Background: Colorectal cancer is the second leading cause of cancer death. Almost
half of the patients present recurrence within 5 years after the treatment of the
primary tumor, the majority, with metastasis. On the other hand, in the search for
new animal models that simulate metastatic cancer, it has been suggested that
fibroblasts immersed in the peritumoral stroma (cancer-associated fibroblasts
(CAFs)), play a relevant role in the development of cancer. The objective of this study
was to identify an adequate animal model to study metastatic colon cancer and the
application of new treatments.
Methods: Human CAFs and normal fibroblasts (NF) for transplant and culture were
obtained from surgical fresh samples of patients with adenocarcinoma of sigmoid
colon. Stromal cell purity was evaluated by morphology and immunostaining with
vimentin (VIM) as a fibroblast marker and anti-proColXIa1 as a specific human
CAF marker. Phenotypic characterization of cultured stromal cells was performed by
co-staining with mesenchymal and epithelial cell markers. For identification in mice,
human CAFs were labeled with the PKH26 red fluorescence dye. Cell line HT-29 was
used as tumor cells. Transplant in the head of the pancreas of 34 SCID mice was
performed in four different groups, as follows: I. 150,000 CAFS (n = 12), IIa.
1.5 million HT29 cells (n = 7), IIb. 150,000 NF+1.5 million HT29 cells (n = 5),
III. 150,000 CAFS+1.5 million HT29 cells (n = 10). After euthanasia performed one
month later, histological analysis was made using hematoxylin–eosin and
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anti-proColXIa1. A histopathological score system based on three features (tumor
volume, desmoplasia and number of metastasized organs) was established to
compare the tumor severity.
Results: The CAFs and NF cultured were proColXIa1+/VIM+, proColXIa1/
alphaSMA+ and proColXIa1+/CK19+ in different proportions without differences
among them, but the CAFs growth curve was significantly larger than that of the NF
(p < 0.05). No tumor developed in those animals that only received CAFs. When
comparing group II (a + b) vs. group III, both groups showed 100% hepatic
metastases. Median hepatic nodules, tumor burden, lung metastases and severity
score were bigger in group III vs group II (a + b), although without being significant,
except in the case of the median tumor volume, that was significantly higher in group
III (154.8 (76.9–563.2) mm3) vs group II (46.7 (3.7–239.6) mm3), p = 0.04. A
correlation was observed between the size of the tumor developed in the pancreas
and the metastatic tumor burden in the liver and with the severity score.
Conclusion: Our experiments demonstrate that cultured CAFs have a higher growth
than NF and that when human CAFs are associated to human tumor cells, larger
tumors with liver and lung metastases are generated than if only colon cancer cells
with/without NF are transplanted. This emphasizes the importance of the tumor
stroma, and especially the CAFs, in the development of cancer.
Subjects Oncology, Surgery and Surgical Specialties
Keywords Xenograft, Animal model, CAFs, Fibroblasts culture, ProColXIa1
INTRODUCTION
Colorectal cancer is the third most frequent cancer worldwide, with 1.8 million estimated
new cases in 2018. In terms of mortality, colorectal cancer is the second leading cause
of cancer death, after lung cancer, with 880,000 deaths in 2018 (Ferlay et al., 2019;
Stewart & Wild, 2014). Colon cancer is three times more frequent than rectal cancer, and
97% of colon tumors are adenocarcinomas (Scientific American Surgery, 2016). Worldwide
there is large geographic variability in incidence, and these differences are similar in
both sexes (Ferlay et al., 2019; Sociedad Española de Oncología Médica, 2017). The highest
rates of colon cancer correspond to industrialized countries (Asociación Española contra
el Cáncer, 2018). Although survival rates of advanced stage tumors have improved
significantly, almost 50% of patients present with cancer recurrence within 5 years
following treatment of the primary tumor, with the majority of these cases having liver
metastases (Rashidi et al., 2000; Roy & Majumdar, 2012).
The objective of this study was to identify an adequate animal model to study metastatic
colon cancer and the application of new treatments. The ideal animal model needs to meet
criteria of technical ease, a high degree of implantation in a short time period, be
reproducible, and with a natural history similar to the human disease. To meet these
requirements and facilitate the development of cancer, the peritumoral stroma and the
fibroblasts immersed in it—cancer-associated fibroblasts (CAFs)—play a relevant role
(Van Pelt et al., 2018;Mukaida & Sasaki, 2016). CAFs constitute a heterogeneous group of
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peritumoral fibroblasts that have properties similar to those of mesenchymal stem cells
(Kalluri, 2016; Valcz et al., 2014; Huang et al., 2014; Öhlund, Elyada & Tuveson, 2014).
It is thought that fibroblasts facilitate tumor growth and favor an immunosuppressive
environment that avoids the elimination of tumor cells and promotes the sequestration of
drugs and the radioprotection of tumor cells (Whittle & Hingorani, 2019). Therefore,
the co-transplant of tumor cells with CAFs could be of interest in animal models of human
cancer. The reasons that justify co-transplanting with CAFs are that they secrete growth
factors, promote angiogenesis, transfer substrates to neighboring cells, and decrease the
activity of natural killer cells to modulate the immune response. Previous evidence has
shown that the conjoint implantation of cancerous cells with CAFs in SCID (severe
combined immune deficiency) mice results in a very aggressive tumor with large local
growth and liver metastases 3–4 weeks post-transplant (Porrero Guerrero, 2017).
This, along with the characteristics mentioned above, led us to develop a highly aggressive
heterotopic human colon adenocarcinoma xenotransplantation model, whose results
we present in this article. The pancreas was selected as the implantation site as it is a site
rich in growth factors that would facilitate local growth and distant growth from the
implanted cells.
MATERIALS AND METHODS
Patient characteristics and surgical samples
The CAFs for transplant were obtained from an 81-year-old woman with moderately
differentiated adenocarcinoma of the sigmoid colon, pT3 pN0. The human fibroblasts
for culture were obtained from three patients: (1) an 80-year-old male with a well-
differentiated mucinous adenocarcinoma of the right colon, pT2 pN0; (2) a 72-year-old
female with a moderately differentiated adenocarcinoma of the sigmoid colon, pT3 pN0;
and (3) a 56-year-old male with a recurrence of moderately differentiated adenocarcinoma
of the sigmoid colon, pT3pN0.
Cell cultures
Colon fibroblasts
Samples were obtained from the tumor area (for other studies), peritumoral area (for
CAFs) and normal area (for “normal fibroblasts”, NF) using different surgical blades to
avoid contamination few minutes after the operation. The lack of tumor cells was verified
by microscopy. The samples were cut into smaller fragments. The establishment of cell
cultures has been published previously (García-Pravia et al., 2013). Briefly, the fragments
were enzymatically digested with collagenase Type I, the pellet was suspended in a
fibroblast culture medium with fetal bovine serum (FBS) as below and antibiotics.
The tissue fragments that had not been digested with collagenase underwent a second
digestion with trypsin and EDTA. Cells obtained were seeded in six-well plates using
fibroblast culture medium and maintained at 37 C in a 5% CO2 incubator. All stromal
cells were used at early passages (passages 3–6). The cell purity of stromal cells was assessed
by morphology and by immunostaining for vimentin. Following counting in the Neubauer
chamber, the cell purity of the stromal cells was evaluated for morphology, and
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immunostaining with VIM as a fibroblast marker, and with anti-proColXIa1 mousse mAb
(DMTX1, Oncomatryx, Derio, Vizcaya, Spain) as a specific marker for human CAFs
(García-Pravia et al., 2013; Galván et al., 2014; García-Ocaña et al., 2012). The remaining
cells were frozen using DMEM +10% FCS and 10% DMSO as cryoprotectant in cryovials.
The cryovials were maintained in a −80 C freezer overnight and then transferred into
a liquid nitrogen container for long-term storage for other studies. Both types of cells
(NF and CAFs), obtained from three patients, were seeded in six-well plates at a rate of
1  104 viable cells per well, using the culture medium previously used. Every two days,
one of the dishes was trypsinized and the cells were counted on a Neubauer chamber.
The wells were not filled in any case, so there was no contact inhibition.
Colon adenocarcinoma cell line
HT-29 cells ( HTB-38; ATCC, Manassas, VA, USA) were cultivated in DMEM standard
media with 10% FBS. All the cultures were carried out in a humidified atmosphere of
5% CO2 in air at 37 C. Culture passages and cell collections were done with trypsin/EDTA
0.05%/0.02% (Biochrom, Cambridge, UK).
Immunocytofluorescence of cultured stromal cells and confocal
microscopy
The methodology used has been described previously (García-Pravia et al., 2013).
In summary, cells were fixed in acetone, dried at room temperature, and then taken into
the wash buffer. The samples were incubated with the anti-proColXIa1 mAb, (DMTX1,
Oncomatryx, Derio, Vizcaya, Spain), Cytokeratin 19 (CK19) antibody, aSMA and
VIM antibody, at room temperature, under the conditions specified in Table 1.
The secondary antibodies used were green anti-mouse Alexa-488 and red anti-rabbit
Alexa-546, and the sections were mounted with mounting medium containing DAPI.
The colocalization was visualized and photographed using a confocal microscope with
specific sources of illumination for each fluorochrome excitation.
Identification of human CAFs inside the pancreas of mice
CAFs were labeled with PKH26 red fluorescence cell dye (Sigma-Aldrich PKH26 Red
Fluorescent Cell Linker Kits for General Cell Membrane Labeling). The labeling vehicle
provided in the kits (Diluent C) was designed to maintain cell viability, while maximizing
dye solubility and staining efficiency during the labeling step. Due to it, cells present
extremely stable fluorescence and PKH26 is the cell linker dye of choice for in vivo cell
Table 1 Summary of antibodies used for immunocytochemistry (IHC).
Primary antibodies (species) Clone Commercial reference Dilution Incubation time (min)
anti-procollagenXIa1 (mAb) 1E8.33 DMTX1/Oncomatryx, Spain 1:400 30
CK 19 (mAb) RCK108 Dako, Denmark 1:50 15
a-SMA (mAb) 1A4 Dako, Denmark Ready to use 20
Vimentin (pAb) C-20 Santa Cruz Biotech, Germany 1:400 10
Note:
mAb, Monoclonal antibody; pAb, Polyclonal antibody.
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tracking studies. PKH26 consists of an aliphatic molecule that is incorporated into the
cell membrane, linked to a rhodamine-like fluorescent dye. The optimum excitation
wavelength is 551 nm and the emission wavelength is 567 nm. The CAFs were injected into
the pancreas of mice. After seven days, mice were sacrificed and tumor samples were
embedded in Tissue-Teck OCT (Thermo, Waltham, MA, USA), and frozen in liquid
nitrogen. Five-micrometer-thick sections were stored at −80 C. Sections were fixed in
acetone (−20 C, 10 min) and incubated with anti-proColXIa1 mAb (Oncomatryx, Derio,
Vizcaya, Spain, 1:400, 30 min) secondary conjugated Alexa 488 (1:500, Invitrogen,
Carlsbad, CA, USA). Nuclei were counterstained with 4,6-diamidino-2-phenylindole
dihydrochloride hydrate (DAPI, Vector Labs, Burlingame, CA, USA). To document the
presence and human origin of CAFs in tumor sections of mice, various sections per mouse
were analyzed by confocal microscopy. PKH26 positive cells presented red fluorescence
and pro-ColXIa1 positive cells presented green fluorescence.
Animals
The transplants were done in immunodeficient male mice, BALB/cJHanHsd-Prdkcscid
SCID strain (Envigo RMS, Spain SL), aged 4–10 weeks. They remained housed in a special
room for immunodepressed mice, on a ventilated rack, and under a laminar flow hood
used for handling.
Transplants
Inhalational anesthesia (isoflurane) and preoperative analgesia (intraperitoneal
buprenorphine 0.05 mg/kg 15 min prior to the intervention) were used. A 1–2 cm
laparotomy was performed and the cell solution was slowly injected (30 s via a 30 G
needle, 50 µl in PBS) into the head of the pancreas at the level of the pylorus.
Following this procedure, meloxicam 1.5–2 mg/kg was administered intraperitoneally.
The buprenorphine and meloxicam doses were repeated every 24 h during two days via the
subcutaneous route.
Experimental design of transplants
Heterotopic transplant in the head of the pancreas of SCID mice
A total of 34 mice were randomly distributed in four groups: I. Twelve animals received
150,000 CAFs; IIa. In seven mice 1.5 million HT29 cells were implanted; IIb. In five
animals 150,000 NF and 1.5 million HT29 cells were transplanted; III. Ten mice received
150,000 CAFs and 1.5 million HT29 cells. To make sure that the CAFs transplants
would not produce tumors on their own, a greater number of animals were included in the
group I. With the aim of removing any potential defects in fibroblasts isolation, aliquots of
the same isolated fibroblasts were concurrently transplanted in all of the experimental
groups. All processes were performed under sterile conditions.
Euthanasia
At one month post-transplant, the mice were euthanized using a CO2 chamber, and
the intestinal and thoracic content removed in block, preserving them in 4%
paraformaldehyde.
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Histological analysis
The samples were analyzed by personnel of the Department of Molecular Histopathology
in Animal Cancer Models (University Institute of Oncology). Specimens were fixed for
24 h in 4% paraformaldehyde at room temperature, embedded in paraffin, sectioned in
sections of 5 µm thickness, and stained with hematoxylin–eosin and anti-proColXIa1
mAb (DMTX1; Oncomatryx, Derio, Vizcaya, Spain). The volume of the tumor which
developed in the pancreas was calculated in mm3 with the formula major axis x
(minor axis)2 x 0.53. To assess the size of liver metastases, each liver was completely cut
into serial sections with a distance between each section of 200 µm. The liver metastases
were evaluated by counting the number that were observed in the histological sections,
classifying their size in small, medium and large, giving to these a value of 1, 2 or 3,
respectively, as a measure of liver tumor burden. A small metastasis size was considered
when the same tumor appeared in a single section (≤400 µm), medium when the
tumor appeared in two consecutive sections (>400 mm and ≤600 µm), and large when the
tumor appeared in three or more sections (>600 µm). Hence, an animal with a liver
containing one small metastasis, one medium and one large metastasis, was classified with
a tumor burden of 6 (1 × 1 + 1 × 2 + 1 × 3 = 6).
We established a histopathological score system from 3 to 9 points, to compare the
tumor severity or aggressiveness, based on three histopathological features (tumor volume,
desmoplasia and number of metastasized organs) according to the following score: tumor
volume feature was:1 = small (<50 mm3); 2 = medium (50–150 mm3) and 3 = large
(>150 mm3); the score given for desmoplasia was: 1 = mild; 2 = mild/moderate;
3 = moderate/severe; the score given for number of metastasized organs was: 1 = 1–2
organs; 2 = 3–4 organs; 3 = >4 organs.
Statistical analysis
Quantitative variables were expressed as medians. Groups were compared using the
Mann–Whitney U test. The association between quantitative variables was assessed using
the regression coefficient and the prediction of one variable from another via the
regression equation. The growth of the cell cultures was analyzed using ANOVA with
Bonferroni correction. All analyses were performed using the programs SPSS 15.0 (SPSS,
Inc., Chicago, IL, USA) for windows and MedCalvs12.
Ethical considerations
All experiments complied with the European Union (2010/63/UE) and Spanish
(RD 53/2013; ECC/556/2015) standards, and were in accordance with the guidelines
of the Committee for the handling and care of animals of the University of Oviedo.
The Committee for the handling and care of animals of the University of Oviedo provided
full approval for this research (PROAE 01/2016). The patients signed consent forms
indicating their willingness to participate in the study.
The extraction of surgical samples was approved by the Hospital Universitario Central
de Asturias ethical committee (Project no 42/12).
Fernando-Macías et al. (2020), PeerJ, DOI 10.7717/peerj.9045 6/18
RESULTS
Characterization of the colon adenocarcinoma CAFs
The fibroblasts for transplantation had positive immunostaining to proColXIa1 (Fig. S1).
Using confocal microscopy, the CAFs and NF cultured were proColXIa1+/VIM+,
proColXIa1+/alphaSMA+ and a small number of cells with the epithelial phenotype
(proColXIa1+/CK19+) (Fig. 1). Figure S2 shows the coexpression in the peritumoral
area of carcinoma in mouse heterotopic xenogratfs of the PKH-26 dye and human
proColXIa1 in CAFs. The CAFs growth curve was significantly larger than that of the NF
(p < 0.05) (Fig. 2). The details of data collected in growth curves are depicted in Table S1
in which the number of cells obtained in each well is represented as the mean of two
determinations.
Figure 1 Confocal microscopy of cultured CAFs. Double fluorecence stain illustrates the presence of:
(A) Cell proCOL11A1+/VIM+, (B) ProCOL11A1+/CK19+ and (C) ProCOL11A1+/alphaSMA+. Red,
proCOL11A1; green, VIM, alphaSMA and CK19; blue, nuclei. Scale bar: (A and B) 20 µm, (C) 100 µm
(X630). Full-size DOI: 10.7717/peerj.9045/fig-1
Figure 2 Growth curves of fibroblasts. Blue, normal fibroblasts; green, CAFs. Cultures obtained from
three patients with adenocarcinoma of colon. Mean ± 2 SEM of three patients with duplicate determi-
nations. Full-size DOI: 10.7717/peerj.9045/fig-2
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Xenotransplants
No tumor developed in those animals that only received CAFs (Table 2). Of the animals
that received HT29 cells without fibroblasts, five died in the initial days following the
procedure. The surviving two mice presented with poorly differentiated carcinomas in
the pancreas with light dysplasia, infiltrating the stomach due to proximity, and liver
metastases; lung metastases also developed in one of the mice in which a focus was also
found in the small intestine (Fig. 3; Table S2). Of the five mice that received HT29 + NF,
one died; the remaining four developed a tumor with liver metastases, and one had
multiple lung and spleen metastases (Fig. 4; Table S3). They all showed occasional tumor
foci in the small and large bowel.
Of the ten animals in the HT29 + CAFs group, two died and one did not develop tumor.
The tumor volume in the pancreas was significantly bigger than in the combined group
that received HT29 with/without NF. All cases with tumor in the pancreas developed
liver metastases with a higher tumor burden than in the other transplant groups, but
without reaching statistical significance, and in more than half lung metastases were
identified. One animal presented with metastases in the spleen, four in the small intestine,
and two in the peritoneum with multiple foci of lymphovascular invasion (Fig. 5; Fig. S3;
Table S4).
The cytological pattern of all of these showed cell and nuclear pleomorphism, with an
increase in the nuclear–cytoplasmic ratio, irregular nuclear membranes, and various
nucleoli. The histological pattern of the mice that received fibroblasts or CAFs was that of
moderately or poorly differentiated carcinoma, with low–moderate dysplasia, some with
vascular invasion, and infiltrating the stomach due to proximity.
Table 2 Summary of results in xenografts.
I. CAFs II*. (HT29) +
(HT29 + NF)
III. HT29 + CAFs p-value II
vs III
No. animals 12 12 (7 + 5) 10
Exitus 0 6 (5 + 1) 2
Tumor incidence (%) 0 100 (6/6) 87.5 (7/8) NS
Tumor volume (mm3) – 3.7; 91.6 8;
28.2; 65.3; 239.6
76.9; 93.7; 143.9; 154.8;
169.9; 207; 563.6
Median tumor volume (mm3)
(min–max)
– 46.7 (3.7–239.6) 154.8 (76.9-563.2) 0.04
Hepatic metastases (%) – 100 (6/6) 100 (7/7)
No. hepatic nodules 1; 6 2; 3; 4; 5 6; 9; 9; 10; 14; 14
Median hepatic nodules (min–max) 3.5 (1–6) 6 (2–11) 0.12
Median tumor burden (min–max) 6.5 (1–12) 10 (6-15) 0.08
Lung metastases (%) – 33 (2/6) 57 (4/7) NS
Severity score (min–max) 5 (3–8) 7 (5–8) 0.06
Note:
CAFS, cancer-associated fibroblasts; NF, normal fibroblasts. *Group II: IIa (HT29) + IIb (HT29 + NF). See explanation in
Study Limitations chapter. Numbers in bold italics correspond to group IIb. Liver tumor burden and severity score: see
text.
Fernando-Macías et al. (2020), PeerJ, DOI 10.7717/peerj.9045 8/18
Median hepatic nodules, tumor burden, lung metastases and severity score were bigger
in group III vs group II, although without being significant, except in the case of the
median tumor volume, that was significantly higher in group III (154.8 (76.9–563.2) mm3)
vs group II (46.7 (3.7–239.6) mm3), p = 0.04. A relationship was observed between the size
of the tumor developed in the pancreas and the metastatic tumor burden in the liver
(y = 0.321 + 4.483 log(x), r = 0.69, p = 0.001) and the severity score (y = 2.231 + 2.008 log
(x), r = 0.79, p < 0.001) (Fig. 6).
DISCUSSION
The possibility of personalized cancer treatment is affected by the heterogeneity of the
primary tumor and that of the metastases, which means that the results of gene and
molecular expression obtained from one area of the tumor are different from those in other
areas of the same tumor, and therefore the behavior cannot be determined from a few
biopsies (Gerlinger et al., 2012). In an attempt to simulate the human disease in animals
and in order to be able to apply new treatments, different animal models of cancer have
been made (Johnson & Fleet, 2013; Taketo & Edelmann, 2009). Animals that have been
genetically modified for this purpose, GEMM, may shed light on the role of different
Figure 3 HT-29 in the pancreas model. (A) Microphotograph of maximal tumor size in pancreatic
tissue (maximal tumor size, score 1) 1.25×, H–E. Red circle, maximal tumor size in pancreatic tissue.
(B) Histological image of poorly differentiated pancreatic adenocarcinoma, 10×, H–E. Malignant epi-
thelial cells isolated or arranged in small or large clusters, with mild-moderate desmoplastic stromal
reaction (score 2). (C) The image shows metastasis of a small cluster of malignant epithelial cells (score 1
of no. of metastasized organs) in: C, liver tissue; D, lung tissue (H–E, 4×). Red circle (C and D) nest of
tumoral cells in liver and lung, respectively. Scale bar: (A) 500 µm; (B and D) 50 µm; (C) 200 µm.
Full-size DOI: 10.7717/peerj.9045/fig-3
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genes in the appearance of this disease. In one of these animal models, it was demonstrated
that cancer metastases precede the formation of the primary tumor (Rhim et al., 2012),
which would be in line with the hypothesis that cancer is a systemic disease from the start;
this is further supported by findings of metastases in patients without being able to localize
the primary tumor. The main disadvantage of these models is that the alterations affect the
germ line, resulting in the possible development of diseases from the embryonic stage.
Furthermore, they develop precancerous or cancerous lesions at other levels (Johnson &
Fleet, 2013).
The initial control of the tumor is an advantage in chemically induced cancers or
cancers induced via implantation of tumor cells (Johnson & Fleet, 2013; Karim & Huso,
2013). In terms of the administration of carcinogenic substances, the process depends
on the duration and dose, and the state of the organism (Karim & Huso, 2013).
One general limitation of these experiments is the scarce development of metastases
(Johnson & Fleet, 2013).
The model most utilized by researchers to trial new treatments is the xenotransplant
of cancerous human cells in immunodepressed animals, usually SCID mice or other
variants, either in the organ where the tumor develops—orthotopic xenotransplant—or
in another anatomic region such as subcutaneous tissue—heterotopic xenotransplant.
An important limitation of this model is that it lacks the influence that part of the immune
system has on the development of the xenotransplant. In xenotransplants, tumor cell lines
or slices of tumor samples extracted from patients, patient derived xenograft (PDX),
are used. These samples are obtained fresh from tumor and should be implanted as soon as
possible within the first 24 h (Rashidi et al., 2000; Fu et al., 1991). PDX has the advantage
Figure 4 HT29 + NF. (A) Mouse necropsy. Great pancreatic tumor distention gallbladder
(Courvoisier–Terrier signe), gastric infiltration. (B) Microphotograph of maximal tumor size in pan-
creatic tissue (maximal tumor size, score 2) 1.25×, H–E. (C) The image shows metastasis of small or
medium clusters of malignant epithelial cells (score 1 of no. of metastasized organs) in: C, liver tissue;
D, lung tissue (H–E, 4×). Scale bar: (B) 500 µm; (C) 200 µm; (D) 50 µm.
Full-size DOI: 10.7717/peerj.9045/fig-4
Fernando-Macías et al. (2020), PeerJ, DOI 10.7717/peerj.9045 10/18
that the animal receives the full tumor repertoire from the patient: tumor and the
peritumoral inflammatory reaction (Katsiampoura et al., 2017). Additionally, these would
be appropriate to trial personalized treatments: the patient’s tumor is transplanted in a
Figure 6 Relationship between pancreatic tumor and hepatic burden (A) or severity score (B).
Regression ecuations. (A) Pancreatic tumor size-hepatic burden and (B) pancreatic tumor size-severity
score. Full-size DOI: 10.7717/peerj.9045/fig-6
Figure 5 HT29 + CAFs. (A) Mouse necropsy. Great pancreatic tumor with liver metastases, distention
gallbladder (Courvoisier–Terrier signe), gastric infiltration. (B) Microphotograph of maximal tumor size
in pancreatic tissue (maximal tumor size, score 3) 1.25×, H–E. Red circle, maximal tumor size in pan-
creatic tissue. (C) Histological image of poorly differentiated pancreatic adenocarcinoma, 10×,
H–E. Malignant epithelial cells isolated or arranged in small or large clusters, with necrosis and moderate
desmoplastic stromal reaction (score 2). Scale bar: (B) 500 µm; (C) 50 µm.
Full-size DOI: 10.7717/peerj.9045/fig-5
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series of animals that are treated with diverse drugs, and the one which best controls the
tumor would be used in the patient (Okada, Vaeteewoottacharn & Kariya, 2018;Williams,
2018). Nevertheless, this method has its limitations as well: it requires the use of animals
that lack an immune system, the stroma that forms is murine and not human, and
sometimes does not develop metastases (Katsiampoura et al., 2017). In addition, its clinical
use is not without difficulties: with slow tumor growth, it has to be transferred to other
animals to have a sufficient number for treatments, need for controls and costs involved.
One of the primary surgical models developed was the heterotopic transplant conducted
in subcutaneous tissue of immunodeficient mice and implanted with human colon cancer
cells. In this model, the growth was easily monitored, however, being situated extra-
abdominally, did not develop metastases (Mittal et al., 2015). Some authors have
utilized this technique as a step prior to conducting an orthotopic transplant, using the
subcutaneous tumor to obtain samples that are then implanted in the colon of other mice
(Mittal et al., 2015; Flatmark et al., 2004; Fodstad, 1991). The splenic capsule and kidney
are also used as sites for implantation (Mittal et al., 2015). The orthotopic model is
considered the one that best simulates the process of human colon cancer development
(Mittal et al., 2015).
In recent years organoids have been developed, which are bodies of cells cultivated
in vitro forming a three-dimensional structure. Their functional and anatomic
characteristics are more like the original organ. They are made from healthy and tumor
stem cells, which allows for the study of its behavior and reaction to drugs in both cases
(Young & Reed, 2016).
To avoid the inconvenience of the scarce tumor appearance, slow development, absence
of metastases and economic cost, that the aforementioned models present, we have trialed
a new xenotransplant model that consists of implanting CAFs obtained from fresh
colon cancer specimens conjointly with HT-29 tumor cells in SCID mice. This model is
very aggressive, and within a few weeks develops a large tumor with liver metastases and
therefore it is possible to start new treatments without delay. Our team has focused its
research on CAFs (García-Pravia et al., 2013;Galván et al., 2014;García-Ocaña et al., 2012;
Fuentes Martínez et al., 2015), and on a protein from the collagen family, collagenXIa1,
which is universally overexpressed in the stroma of epithelial tumors (Vázquez-Villa
et al., 2015), namely in the cytoplasm of the CAFs and not in the epithelial cells.
The antibody anti-proColXIa1 stains CAFs specifically (García-Ocaña et al., 2012), in
contrast to other mesenchymal markers such as VIM and aSMA that stains a wide variety
of fibroblasts, including NF, fibroblasts from inflammatory areas, and in lesions, etc.
In tissue, whereas non-peritumoral fibroblasts are stained with anti-VIM and anti aSMA,
the CAFs are also stained with anti-proColXIa1; nevertheless, in cultures these differences
in the expression of markers between the different groups disappear. In a pancreatic
cancer model, cultivating fibroblasts from CAPAN-1 cells, a higher proliferation of these
cells was observed in the presence of peritumoral fibroblasts compared with non-tumor
fibroblasts or without the presence of fibroblasts (Porrero Guerrero, 2017); which would be
consistent with the results of the xenotransplants associated with the CAFs. The human
fibroblasts transplanted in animals can be visualized using anti-proColXIa1 and be
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distinguished from those of the animals, as this antibody is specifically human and does
not cross-react with other species (Fernández-García et al., 2014), which would allow the
monitoring over time of these cells in the animal. Another feature of anti-proColXIa1
is that it marks cells that are in epithelial–mesenchymal transition showing double staining
for epithelial (CK19) and mesenchymal (VIM) (García-Pravia et al., 2013).
The resulting cultured cells in our experiments were fibroblasts both morphologically
and in terms of their phenotypic characteristics, staining for nonspecific mesenchymal
markers such as VIM; specific markers of inflammation, such as smooth muscle alpha-
actin; and, as well as the specific marker for CAFs, procollagenXIa1. The percentage of
mesenchymal cells marked exclusively with CK19 was scarce, although it was possible
to observe cells with a double phenotype procollagenXIa1+/CK19+, characteristic of cells
in epithelial–mesenchymal transition. As our samples of CAFs were not significantly
contaminated with tumor cells, this shows why the transplants conducted with only
fibroblasts did not develop any tumor. In other models of xenotransplants, tumor did
not develop either with the administration of CAFs (Porrero Guerrero et al., 2015;
Rodríguez Uría et al., 2018). The fibroblasts of normal tissue did not stain for SMA nor
for procollagenXIa1; however, under the artificial conditions of the culture, some
fibroblasts obtained from non-tumor areas acquired positivity for those markers due to the
artificial conditions to which they had been subjected.
According to the hypothesis that the tumor stroma and fibroblasts in particular,
promote tumor progression, we coupled CAFs cultivated from our surgical samples with
HT29 cells in this new transplant model and chose the pancreas as the implantation site, as
in this organ very aggressive tumors develop with a high metastatic capacity and high
mortality. This is due to various mechanisms, among which are the influence of the
substances secreted by the pancreatic islets that stimulate cell growth (Kim & Herbrok,
2001). In our research group, models of pancreatic cancer have been developed previously
(Porrero Guerrero, 2017). Given our training in this technique we decided to apply the
heterotopic model of colon cancer. We conducted a control group with CAFs transplant
without tumor cells to verify that these cells alone are not capable of developing tumor.
In the subsequent experimental groups, cell lines of colon cancer were transplanted, alone
and coupled with NF or CAFs. In both models, tumors and multiple metastases were
obtained, with the group including CAFs producing the largest size tumors.
CONCLUSIONS
In conclusion, our experiments demonstrate that the association of human peritumoral
fibroblasts with human tumor cell generates, early, larger tumors with liver and lung
metastases, than if only colon cancer cells are transplanted. This demonstrates the
importance of the tumor stroma and especially the CAFs, in the development of colon
cancer.
Study limitations
The loss of animals in the HT29 group made it impossible to compare them directly with
the animals that received NF and CAFs, although in other experiments it was found
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that tumor development and metastases were lower than when associated with CAFs
(Porrero Guerrero et al., 2013, 2015; Rodríguez Uría et al., 2018; ); hence, we decided to
regroup the HT29 and HT29 + NF animals in one group, assuming that the NF would not
influence tumor growth as much as the CAFs.
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